NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
NeoGenomics (NASDAQ: NEO), a leading oncology testing services company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Chris Smith will deliver a presentation with a Q&A session on Wednesday, January 15, at 1:30 p.m. PT/4:30 p.m. ET. The event will be accessible through a live webcast, with a replay available on the company's Investor Relations website at ir.neogenomics.com.
NeoGenomics (NASDAQ: NEO), una delle principali aziende di servizi di test oncologici, ha annunciato la sua partecipazione al 43° Annuale J.P. Morgan Healthcare Conference a San Francisco. Il CEO Chris Smith terrà una presentazione seguita da una sessione di domande e risposte mercoledì 15 gennaio, alle 13:30 ora del Pacifico / 16:30 ora dell'Est. L'evento sarà accessibile tramite un webcast dal vivo, con una registrazione disponibile sul sito web delle Relazioni con gli Investitori dell'azienda su ir.neogenomics.com.
NeoGenomics (NASDAQ: NEO), una de las principales empresas de servicios de pruebas oncológicas, ha anunciado su participación en la 43ª Conferencia Anual de Atención Médica de J.P. Morgan en San Francisco. El CEO Chris Smith presentará una conferencia con una sesión de preguntas y respuestas el miércoles 15 de enero a la 1:30 p.m. PT / 4:30 p.m. ET. El evento será accesible a través de una transmisión en vivo, con una repetición disponible en el sitio web de Relaciones con Inversores de la empresa en ir.neogenomics.com.
NeoGenomics (NASDAQ: NEO), 선도적인 종양학 테스트 서비스 회사가 샌프란시스코에서 열리는 제43회 JP 모건 헬스케어 컨퍼런스에 참가한다고 발표했습니다. CEO 크리스 스미스는 1월 15일 수요일 오후 1시 30분 PT / 오후 4시 30분 ET에 프레젠테이션과 질의응답 세션을 진행할 예정입니다. 이 행사는 생중계를 통해 접근 가능하며, 회사의 투자자 관계 웹사이트 ir.neogenomics.com에서 재생이 가능합니다.
NeoGenomics (NASDAQ: NEO), une entreprise de premier plan dans les services de tests en oncologie, a annoncé sa participation à la 43e Conférence annuelle J.P. Morgan Healthcare à San Francisco. Le PDG Chris Smith fera une présentation suivie d'une session de questions-réponses le mercredi 15 janvier à 13h30 PT / 16h30 ET. L'événement sera accessible via un webcast en direct, avec une rediffusion disponible sur le site web des Relations Investisseurs de l'entreprise à ir.neogenomics.com.
NeoGenomics (NASDAQ: NEO), ein führendes Unternehmen für Onkologie-Testdienstleistungen, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Conference in San Francisco bekannt gegeben. CEO Chris Smith wird am Mittwoch, den 15. Januar, um 13:30 Uhr PT / 16:30 Uhr ET eine Präsentation mit einer Frage- und Antwortsitzung halten. Die Veranstaltung wird über ein Live-Webcast zugänglich sein, mit einer Wiederholung auf der Investor-Relations-Website des Unternehmens unter ir.neogenomics.com.
- None.
- None.
The presentation will be webcast live and accessible online via this link. A replay will be available on the Investor Relations section of the Company’s website at ir.neogenomics.com.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostic Division also serves pharmaceutical clients in clinical trials and drug development.
Headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250106693170/en/
Investor Contact
Kendra Sweeney
kendra.sweeney@neogenomics.com
Media Contact
Andrea Sampson
asampson@sampsonprgroup.com
Source: NeoGenomics, Inc.
FAQ
When is NeoGenomics (NEO) presenting at the 2024 J.P. Morgan Healthcare Conference?
How can investors watch NeoGenomics' (NEO) J.P. Morgan Healthcare Conference presentation?
What will be covered in NeoGenomics' (NEO) presentation at the J.P. Morgan Healthcare Conference?
Where is the 43rd J.P. Morgan Healthcare Conference featuring NeoGenomics (NEO) being held?
